Radio and PodcastRadio and PodcastLive Radio & Podcasts
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis artwork
Science & Medicine

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis

FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Jan 2, 20255:00Science & Medicine

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis

About This Episode

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evalu...

Podcast

This episode belongs to FDA Drug Safety Podcasts.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jan 2, 2025, 5:00 long, audio available.

Related Episodes

Continue listening to more episodes from FDA Drug Safety Podcasts.